Table 1 Pan-Immune-Inflammation Value (PIV) according to patients’ and disease baseline characteristics.
Characteristics | Total (N = 438) N (%) | PIV low (N = 208) N (%) | PIV high (N = 230) N (%) | P* |
|---|---|---|---|---|
Age (years) | 0.111 | |||
Median | 62 | 62 | 60 | |
IQR | 53–68 | 55–68 | 52–67 | |
Gender | 0.608 | |||
Female | 163 (37) | 80 (38) | 83 (36) | |
Male | 275 (63) | 128 (62) | 147 (64) | |
ECOG PS | <0.001 | |||
0 | 356 (81) | 186 (89) | 170 (74) | |
1 | 82 (19) | 22 (11) | 60 (26) | |
Prior adjuvant treatment | 0.127 | |||
No | 376 (86) | 173 (83) | 203 (88) | |
Yes | 62 (14) | 35 (17) | 27 (12) | |
Primary tumour resected | <0.001 | |||
No | 133 (30) | 45 (22) | 88 (38) | |
Yes | 305 (70) | 163 (78) | 142 (62) | |
Liver-limited disease | 0.066 | |||
No | 307 (70) | 137 (66) | 170 (74) | |
Yes | 131 (30) | 71 (34) | 60 (26) | |
Synchronous metastases | 0.003 | |||
No | 97 (22) | 59 (28) | 38 (17) | |
Yes | 341 (78) | 149 (72) | 192 (83) | |
Number of metastatic sites | 0.032 | |||
1 | 181 (41) | 97 (47) | 84 (37) | |
>1 | 257 (59) | 111 (53) | 146 (63) | |
Primary tumour sidedness | 0.240 | |||
Left | 330 (75) | 162 (78) | 168 (73) | |
Right | 108 (25) | 46 (22) | 62 (27) | |
RAS/BRAF status | 0.514 | |||
RAS/BRAF wild-type | 276 (63) | 127 (61) | 149 (65) | |
RAS mut | 146 (33) | 75 (36) | 71 (31) | |
BRAF mut | 16 (4) | 6 (3) | 10 (4) | |
Study | 0.659 | |||
Valentino | 207 (47) | 112 (54) | 119 (52) | |
TRIBE | 231 (53) | 96 (46) | 111 (48) | |
Chemotherapy backbone | 0.324 | |||
Doublet | 321 (73) | 157 (75) | 164 (71) | |
Triplet | 117 (27) | 51 (25) | 66 (29) |
